Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 335

Similar articles for PubMed (Select 15693656)

1.

Monitoring response to treatment in patients utilizing PET.

Avril NE, Weber WA.

Radiol Clin North Am. 2005 Jan;43(1):189-204. Review.

PMID:
15693656
2.

Response to therapy in breast cancer.

Avril N, Sassen S, Roylance R.

J Nucl Med. 2009 May;50 Suppl 1:55S-63S. doi: 10.2967/jnumed.108.057240. Epub 2009 Apr 20. Review.

3.

Functional PET imaging in cancer drug development.

Avril N, Propper D.

Future Oncol. 2007 Apr;3(2):215-28. Review.

PMID:
17381421
4.

Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.

Facey K, Bradbury I, Laking G, Payne E.

Health Technol Assess. 2007 Oct;11(44):iii-iv, xi-267. Review.

5.

Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.

Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N.

J Nucl Med. 2005 Jul;46(7):1144-50.

6.
7.

18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.

Krause BJ, Herrmann K, Wieder H, zum Büschenfelde CM.

J Nucl Med. 2009 May;50 Suppl 1:89S-96S. doi: 10.2967/jnumed.108.057232. Epub 2009 Apr 20. Review.

8.

Positron emission tomography imaging of brain tumors.

Wong TZ, van der Westhuizen GJ, Coleman RE.

Neuroimaging Clin N Am. 2002 Nov;12(4):615-26. Review.

PMID:
12687915
9.

Monitoring response to therapeutic interventions in patients with cancer.

Herrmann K, Krause BJ, Bundschuh RA, Dechow T, Schwaiger M.

Semin Nucl Med. 2009 May;39(3):210-32. doi: 10.1053/j.semnuclmed.2008.12.001. Review.

PMID:
19341841
10.

Assessing tumor response to therapy.

Weber WA.

J Nucl Med. 2009 May;50 Suppl 1:1S-10S. doi: 10.2967/jnumed.108.057174. Epub 2009 Apr 20. Review.

11.

PET monitoring of therapy response in head and neck squamous cell carcinoma.

Schöder H, Fury M, Lee N, Kraus D.

J Nucl Med. 2009 May;50 Suppl 1:74S-88S. doi: 10.2967/jnumed.108.057208. Epub 2009 Apr 20. Review.

12.
13.

Positron emission tomography for radiation treatment planning.

Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, Zimmermann FB, Schwaiger M, Molls M.

Strahlenther Onkol. 2005 Aug;181(8):483-99. Review.

PMID:
16044216
14.
15.

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Wahl RL, Jacene H, Kasamon Y, Lodge MA.

J Nucl Med. 2009 May;50 Suppl 1:122S-50S. doi: 10.2967/jnumed.108.057307. Review.

16.

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.

Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC.

Clin Cancer Res. 2005 Apr 15;11(8):2785-808. Review.

17.

[Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].

Oriuchi N, Higuchi T, Endo K, Tsukamoto N, Matsuda H, Kuji I, Murakami K, Nakajima K.

Kaku Igaku. 2009 Jun;46(2):96-9. Japanese.

PMID:
19637820
18.

The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies.

Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR.

Gastric Cancer. 2008;11(1):1-9. doi: 10.1007/s10120-007-0448-1. Epub 2008 Mar 29. Review.

PMID:
18373171
19.

PET in breast cancer.

Flanagan FL, Dehdashti F, Siegel BA.

Semin Nucl Med. 1998 Oct;28(4):290-302. Review.

PMID:
9800236
20.

Quantitative assessment of tumor metabolism using FDG-PET imaging.

Weber WA, Schwaiger M, Avril N.

Nucl Med Biol. 2000 Oct;27(7):683-7. Review.

PMID:
11091112
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk